The FDA enforcement report, dated 2 September, lists a Class II recall of clobetasol propionate cream USP 0.05% in 60 g tubes, manufactured for Lupin Pharmaceuticals in the United States, for failed content uniformity specifications. The recall is ongoing.
Content uniformity failure means the amount of steroid may vary across the product. A Class II recall is one where use may cause temporary or reversible health effects and serious harm is unlikely. This concerns specific US-market lots, not clobetasol as a molecule. Whether any Indian-market batches are affected is unknown; CDSCO has not issued a related notice.
- This is a manufacturing-quality recall of US-market clobetasol cream lots, not a new safety warning about clobetasol.
- Content uniformity failure means the steroid dose per application may be uneven.
- Unexpected lack of response or excess irritation on a new tube is worth a check of the batch.
- No CDSCO action has been reported for the Indian market.
Why it matters
A variable-strength super-potent steroid can look like treatment failure or cause unexpected atrophy.
Don't overread it
A Class II quality recall of specific US lots is not evidence of a problem with clobetasol itself.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for dermatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free